EDMONTON, July 14 /CNW/ - Ceapro Inc. (TSX-V: CZO) today announced the appointment of Mr. Shawn McMillan as Corporate Secretary. Shawn will continue to serve as Controller of Ceapro Inc. "This is an exciting time for Ceapro as our business continues to expand and we are pleased to have Shawn play an expanded role on our team," said Dr. Mark Redmond, Ceapro's President and CEO. "We are focused on growth, and this year looks promising as we roll out new products such as CeaProve(TM), our diabetes management technology." Shawn earned his Bachelor of Commerce degree in Accounting from the University of Alberta in 2002. Articling with both Collins Barrow Chartered Accountants and Deloitte and Touche LLP, he obtained his Chartered Accountant designation in 2005. Shawn joined Ceapro as Controller in April 2005. About Ceapro Inc. Ceapro Inc., an innovation-driven biotechnology company, develops and commercializes organic products for medical, cosmetic, and animal health industries using proprietary technology and natural, renewable resources. Based in Edmonton, Alberta, Ceapro is one of Alberta Venture's Fastest Growing Companies for 2004 and 2005 and is one of Profit Magazine's Next 100 Companies. Ceapro is also the recipient of the ASTech Award for Outstanding Commercial Achievement for companies with annual sales of less than $25 million. Ceapro's shares trade on the TSX Venture Exchange under the symbol CZO. To learn more about Ceapro, log on to our website at www.ceapro.com. Shares Outstanding: 36,355,950, Recent Close: $0.28. The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or the accuracy of this news release. This release may contain forward-looking statements. Various factors could cause actual results to differ materially from those projected in forward-looking statements. Although the Company believes that the forward- looking statements contained herein are reasonable, it can give no assurance that the Company's expectations are correct. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. %SEDAR: 00010110E
Ceapro announces officer appointment
Earlier from Ceapro
- Ceapro Announces Highlights of Today's Annual General and Special Meeting
- Ceapro to present at BioFinance conference
- Ceapro announces 2004 financial results
- Ceapro receives further investment from AVAC Ltd.
- Ceapro announces new Controller
Later from Ceapro
- Ceapro Announces Granting of Stock Options
- Ceapro announces 2005 second quarter financial results
- Ceapro announces adoption of CeaProve(TM) in global Glycemic Index study
- Ceapro to present CeaProve(TM) at Canadian Diabetes Association conference
- Ceapro announces 2005 third quarter financial results
Follow Ceapro into a list and get an email when it puts out news.
Follow Ceapro